Literature DB >> 24271881

Clinical and biological relevance of statin-mediated changes in HDL metabolism.

Benoit J Arsenault1, S Matthijs Boekholdt.   

Abstract

Although prospective studies consistently show that individuals with low levels of high-density lipoprotein (HDL) cholesterol are at increased cardiovascular risk, it is still not clear whether or not this relationship still holds in patients treated with statins who have achieved optimal low-density lipoprotein cholesterol levels. Additionally, the hypothesis that statin-mediated increases in HDL cholesterol levels have a impact on cardiovascular risk has not been clearly demonstrated. Statin therapy has little impact on the cholesterol content carried by HDL in the bloodstream (i.e., HDL cholesterol levels), but statins can induce a significant redistribution of HDL particle size, particle concentration, and physicochemical and functional properties. Our objective is to summarize the evidence arising from epidemiological, clinical, and experimental studies that suggests a potential role for statin therapy in the modulation of parameters of HDL metabolism and reverse cholesterol transport.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24271881     DOI: 10.1007/s11883-013-0379-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  46 in total

1.  Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.

Authors:  G Martin; H Duez; C Blanquart; V Berezowski; P Poulain; J C Fruchart; J Najib-Fruchart; C Glineur; B Staels
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

Authors:  G Walldius; I Jungner; I Holme; A H Aastveit; W Kolar; E Steiner
Journal:  Lancet       Date:  2001-12-15       Impact factor: 79.321

3.  Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.

Authors:  Steven A Grover; Mohammed Kaouache; Lawrence Joseph; Philip Barter; Jean Davignon
Journal:  Arch Intern Med       Date:  2009-10-26

4.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

Authors:  Rachel H Mackey; Philip Greenland; David C Goff; Donald Lloyd-Jones; Christopher T Sibley; Samia Mora
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

5.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

6.  Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

Authors:  S Matthijs Boekholdt; Benoit J Arsenault; Samia Mora; Terje R Pedersen; John C LaRosa; Paul J Nestel; R John Simes; Paul Durrington; Graham A Hitman; K M A Welch; David A DeMicco; Aeilko H Zwinderman; Michael B Clearfield; John R Downs; Andrew M Tonkin; Helen M Colhoun; Antonio M Gotto; Paul M Ridker; John J P Kastelein
Journal:  JAMA       Date:  2012-03-28       Impact factor: 56.272

7.  Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia.

Authors:  Alexina Orsoni; Elise F Villard; Eric Bruckert; Paul Robillard; Alain Carrie; Dominique Bonnefont-Rousselot; M John Chapman; Geesje M Dallinga-Thie; Wilfried Le Goff; Maryse Guerin
Journal:  J Lipid Res       Date:  2012-02-15       Impact factor: 5.922

8.  Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men.

Authors:  Jean-François Mauger; Patrick Couture; Marie-Eve Paradis; Benoît Lamarche
Journal:  Atherosclerosis       Date:  2005-01       Impact factor: 5.162

9.  Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients.

Authors:  Bela F Asztalos; Katalin V Horvath; Judith R McNamara; Paul S Roheim; Joel J Rubinstein; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2002-10       Impact factor: 5.922

10.  The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.

Authors:  S S Soedamah-Muthu; H M Colhoun; M J Thomason; D J Betteridge; P N Durrington; G A Hitman; J H Fuller; K Julier; M I Mackness; H A W Neil
Journal:  Atherosclerosis       Date:  2003-04       Impact factor: 5.162

View more
  1 in total

1.  Associations Between 20-Year Lipid Variability Throughout Young Adulthood and Midlife Cognitive Function and Brain Integrity.

Authors:  Adina Zeki Al Hazzouri; Michelle R Caunca; Neal Jawadekar; Leslie Grasset; Tali Elfassy; Michelle C Odden; Chenkai Wu; Martine Elbejjani; Lenore Launer; Kristine Yaffe
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-01-07       Impact factor: 6.053

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.